Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Digoxin

FDA-approved product (injectable, injection), marketed as Digoxin, Digoxin Pediatric, Lanoxicaps and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Digoxin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atrial fibrillation
  • Cardiovascular disease
  • Congestive heart failure
  • Heart failure

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Digitalis glycosides
FDA pharmacologic class
Cardiac Glycoside FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis41.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Digoxin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Digoxin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial

    NCT00578617 · start 2006-09

    Registered record
    Registry ID
    NCT00578617
    Conditions
    Atrial Fibrillation; Arrhythmia
    Interventions
    Rate Control; Ablation Therapy; Rate Control; Rate control; Rate control; Rate control; Rate Control; Rate Control; Rate Control; Rhythm Control; Rhythm control; Rhythm control; Rhythm control; Rhythm control; Rhythm control
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-09
    Completion
    2010-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Arrhythmia
    InterventionRate Control; Ablation Therapy; Rate Control; Rate control +11 more
    PhaseNot applicable
    Registry statusCompleted

  • Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer

    NCT00281021 · start 2006-02

    Registered record
    Registry ID
    NCT00281021
    Conditions
    Carcinoma, Non-Small Cell Lung
    Interventions
    Erlotinib plus Digoxin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2006-02
    Completion
    2010-12
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small Cell Lung
    InterventionErlotinib plus Digoxin
    PhasePhase 2
    Registry statusTerminated

  • A Study to Investigate the Effect of YM150 on the Plasma Concentration of Digoxin in Healthy Subjects

    NCT01514812 · start 2006-02

    Registered record
    Registry ID
    NCT01514812
    Conditions
    Healthy; Pharmacokinetic of Digoxin
    Interventions
    YM150; placebo; digoxin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-02
    Completion
    2006-04
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy; Pharmacokinetic of Digoxin
    InterventionYM150; placebo; digoxin
    PhasePhase 1
    Registry statusCompleted

  • Retrospective Evaluation of Carvedilol Versus Captopril in CHF Patients

    NCT00249067 · start 2005-10

    Registered record
    Registry ID
    NCT00249067
    Conditions
    Heart Failure; Heart Murmurs
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2005-10
    Completion
    2005-10
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure; Heart Murmurs
    InterventionNot recorded
    PhaseNot recorded
    Registry statusTerminated

  • Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)

    NCT00000556 · start 1995-03

    Registered record
    Registry ID
    NCT00000556
    Conditions
    Arrhythmia; Atrial Fibrillation; Cardiovascular Diseases; Heart Diseases
    Interventions
    amiodarone; sotalol; propafenone; flecainide; quinidine; moricizine; disopyramide; procainamide; adrenergic beta antagonists; verapamil; diltiazem; digoxin; catheter ablation; pacemaker, artificial
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1995-03
    Completion
    2002-09
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArrhythmia; Atrial Fibrillation; Cardiovascular Diseases; Heart Diseases
    Interventionamiodarone; sotalol; propafenone; flecainide +10 more
    PhasePhase 3
    Registry statusCompleted